Bruker Corporation — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016; financial statements are unaudited. Bruker designs and manufactures scientific instruments and analytical and diagnostic solutions. Bruker Scientific Instruments (BSI) accounted for about 93% of quarterly revenue; Bruker Energy & Supercon Technologies (BEST) represented the remainder.
Key financial metrics
| Metric | Q1 2016 | Q1 2015 / comparison |
|---|---|---|
| Revenue | $375.4 million | $353.5 million; up 6.2%. Organic growth, a non-GAAP measure, was 5.6%. |
| Gross profit / margin | $166.8 million / 44.4% | $160.2 million / 45.3%. |
| Operating income / margin | $34.0 million / 9.1% | $15.2 million / 4.3%. |
| Net income attributable to Bruker / diluted EPS | $23.6 million / $0.14 | $6.5 million / $0.04. |
| Operating cash flow / free cash flow | $(14.0) million / $(22.0) million | Operating cash flow was $27.0 million in Q1 2015. |
| Cash, cash equivalents and short-term investments | $420.5 million at March 31 | $468.3 million at December 31, 2015. |
| Total debt | $302.2 million at March 31 | $265.8 million at December 31, 2015. Cash and short-term investments exceeded debt by $118.3 million. |
Current assets were $1,225.4 million and current liabilities $541.7 million at March 31. The company reported $558.0 million available under revolving credit facilities and was in compliance with debt covenants; leverage and interest coverage ratios were 1.1 and 15.9, respectively.
Material changes versus the prior comparable period
- Revenue growth was driven mainly by BSI, whose revenue increased 7.0% to $350.4 million. BEST revenue declined 1.1% to $27.2 million.
- BSI growth reflected BioSpin orders, pricing and a first shielded ultra-high-field gigahertz NMR system, and improved CALID sales. Weaker demand in Nano markets—including industrial, academic research and data storage—partly offset gains. BEST operating income fell to approximately zero from $1.0 million.
- Gross margin declined 0.9 percentage points, primarily from product mix and weaker Nano demand. Operating income increased as operating expenses fell and prior-year other charges were lower.
- Q1 2015 included a $10.2 million non-cash pension settlement charge; Q1 2016 did not. Q1 2016 other charges were $4.0 million, including $2.2 million of IT transformation costs and $1.8 million of restructuring charges.
- Net income benefited from a lower effective tax rate: 16.9% versus 41.0%, mainly reflecting recognition of previously uncertain tax benefits after tax audits closed and changes in jurisdictional earnings mix.
Outlook, commentary and risks
- Management said existing cash and credit facilities should support operating and investing needs for at least the next 12 months. No specific revenue or earnings guidance was provided in the filing.
- The 2015 BioSpin restructuring reduced headcount by about 9%; related costs were substantially complete by March 31. Management expects approximately $10 million in annualized savings.
- Negative operating cash flow reflected working-capital needs, including inventory build, timing of customer advances and system acceptance, tax payments associated with 2015 European cash repatriation, and incentive bonus payments. Management cited order and payment timing as factors that can make quarterly results fluctuate.
- The company repurchased 3.38 million shares for $83.1 million during the quarter. It also paid its first quarterly dividend of $0.04 per share and said it targets $0.16 annually, subject to board discretion. Further repurchases may be funded from cash, operating cash flow and borrowings.
- Risks include foreign-exchange exposure, weaker demand in certain Nano markets, commodity-price increases affecting superconductors, and customer order, installation and acceptance timing. The company reported no material changes to previously disclosed risk factors and no material pending legal proceedings.
Important facts for investors to verify
- Whether reported organic revenue growth and non-GAAP margin measures reconcile to GAAP results and persist in subsequent quarters.
- Whether negative free cash flow reverses as inventory, customer advances and system acceptance timing normalize.
- Progress toward the expected $10 million annualized restructuring savings and the remaining restructuring reserve.
- Execution of share repurchases and dividends alongside liquidity, debt maturities and the company’s ability to maintain covenant compliance.
- Whether weakness in Nano markets, foreign-exchange movements and the lower effective tax rate materially affect future results.